Jeroen V. Koomen

Jeroen V. Koomen

Auto-generated profile, based on publicly available information

Jeroen V. Koomen

Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in British Journal of Anaesthesia
Verified
Journal Article
Open access
HSHong Su
Hong Su
JKJeroen V. Koomen
Jeroen V. Koomen
DEDouglas J. Eleveld
Douglas J. Eleveld
MSMichel M.R.F. Struys
Michel M.R.F. Struys
PCPieter J. Colin
Pieter J. Colin
Propofol and remifentanil are frequently combined for the induction and maintenance of general anaesthesia. Both propofol and remifentanil cause vasodilation and potentially reduce arterial BP. We aimed to develop a mechanism-based model that characterises the haemodynamic interactions between remifentanil and propofol. Data from two clinical trials in healthy volunteers were analysed using remifentanil-alone, propofol-alone, and combination groups. We evaluated remifentanil effects on haemodynamics using a previously developed mechanism-based haemodynamic model of propofol. The interaction between propofol and remifentanil was explored using the principles of the general pharmacodynamic interaction (GPDI) model. Remifentanil alone increased the dissipation rate of total peripheral resistance by 50% at 3.0 ng ml-1. Additionally, the dissipation rates of HR and stroke volume were attenuated by 4.8% and 4.9% per 1 ng ml-1 increase in remifentanil concentration, respectively. The maximal effect of propofol alone in decreasing the production rate of total peripheral resistance was 78%, which decreased to 32% when combined with remifentanil 4 ng ml-1. The effects of remifentanil on HR and stroke volume were attenuated by propofol with maximum decreases of 11.9% and 21.2%, respectively. Goodness-of-fit plots and prediction-corrected visual predictive check plots showed good predictive performance of the models. The structure of the previous mechanism-based haemodynamic model for propofol was able to describe the effects of remifentanil alone on haemodynamic variables. The GPDI model provided a good framework for characterising the pharmacodynamic interaction between remifentanil and propofol on haemodynamic properties. NCT02043938; NCT03143972.

30 April 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
DEDouglas J. Eleveld
Douglas J. Eleveld
PCPieter J. Colin
Pieter J. Colin
JBJohannes P. Van Den Berg
Johannes P. Van Den Berg
JKJeroen V. Koomen
Jeroen V. Koomen
TSThomas Stoehr
Thomas Stoehr
MSMichel M.R.F. Struys
Michel M.R.F. Struys
Pharmacokinetic-pharmacodynamic (PK-PD) models of remimazolam and their covariate relationships are useful for understanding drug disposition and predicting drug effects. Although clinical studies have shown that remimazolam induction doses decline with advancing age, this property is not reflected in existing models. The purpose of this investigation was to develop a PK-PD model for remimazolam and perform covariate analysis to maximise its utility across broad, diverse populations and to evaluate its consistency with clinical observations of drug dosing. Arterial and venous concentrations of remimazolam and its metabolite, Modified Observer's Assessment of Alertness and Sedation score and bispectral index were determined in 20 studies. Final population models were developed with covariate analysis. Simulations of drug administration for sedation and anaesthesia for this and previously published models were compared with the results of clinical studies. Model development proceeded from 933 individuals aged 6-93 yr and weight 21-171 kg. PK data from studies with extracorporeal membrane oxygenation and treatment in ICU were considered in a post hoc analysis. Simulations of target-controlled infusion with the final model targeting sedation (Modified Observer's Assessment of Alertness and Sedation score 2 or 3) or anaesthesia (bispectral index 50) showed drug administration declining with age consistent with clinical observations. A PK-PD model for remimazolam was developed for a broad, diverse population. Dosing and target concentrations are proposed that are clinically useful for anaesthesia and sedation, especially for target-controlled infusion administration.

30 March 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
JKJeroen V. Koomen
Jeroen V. Koomen
JSJasper Stevens
Jasper Stevens
NMNael M. Mostafa
Nael M. Mostafa
HPHans‐Henrik Parving
Hans‐Henrik Parving
DZDick de Zeeuw
Dick de Zeeuw
HHHiddo Heerspink
Hiddo Heerspink
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR‐JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d of atrasentan in 161 patients with type 2 diabetes and kidney disease. Individual pharmacokinetic parameters were estimated using a population pharmacokinetic approach. Subsequently, changes in the urinary albumin‐to‐creatinine ratio (UACR) and bodyweight from baseline after 2 weeks' exposure were modelled as a function of the pharmacokinetic parameters. The 0.75 and 1.25 mg doses showed a mean UACR reduction of 34.0% and 40.1%, whereas mean bodyweight increased by 0.9 and 1.1 kg, respectively. A large variation between individuals was observed in the UACR and bodyweight responses. Individual pharmacokinetic parameters correlated significantly with both individual UACR and bodyweight responses ( P < .01). The individual response curves for UACR and bodyweight crossed at approximately the mean trough concentration of 0.75 mg atrasentan, indicating that 0.75 mg/d of atrasentan is the optimal dose for kidney protection with maximal efficacy (albuminuria reduction) and safety (minimal sodium retention).

12 June 2023 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
JKJeroen V. Koomen
Jeroen V. Koomen
TKTim J. Knobbe
Tim J. Knobbe
TZTanja R. Zijp
Tanja R. Zijp
DKDaan Kremer
Daan Kremer
CGC. Tji Gan
C. Tji Gan
TITransplantLines Investigators
TransplantLines Investigators
Background and Objective Historically, dosing of tacrolimus is guided by therapeutic drug monitoring (TDM) of the whole blood concentration, which is strongly influenced by haematocrit. The therapeutic and adverse effects are however expected to be driven by the unbound exposure, which could be better represented by measuring plasma concentrations. Objective We aimed to establish plasma concentration ranges reflecting whole blood concentrations within currently used target ranges. Methods Plasma and whole blood tacrolimus concentrations were determined in samples of transplant recipients included in the TransplantLines Biobank and Cohort Study. Targeted whole blood trough concentrations are 4–6 ng/mL and 7–10 ng/mL for kidney and lung transplant recipients, respectively. A population pharmacokinetic model was developed using non-linear mixed-effects modelling. Simulations were performed to infer plasma concentration ranges corresponding to whole blood target ranges. Results Plasma (n = 1973) and whole blood (n = 1961) tacrolimus concentrations were determined in 1060 transplant recipients. A one-compartment model with fixed first-order absorption and estimated first-order elimination characterised observed plasma concentrations. Plasma was linked to whole blood using a saturable binding equation (maximum binding 35.7 ng/mL, 95% confidence interval (CI) 31.0–40.4 ng/mL; dissociation constant 0.24 ng/mL, 95% CI 0.19–0.29 ng/mL). Model simulations indicate that patients within the whole blood target range are expected to have plasma concentrations (95% prediction interval) of 0.06–0.26 ng/mL and 0.10–0.93 ng/mL for kidney and lung transplant recipients, respectively. Conclusion Whole blood tacrolimus target ranges, currently used to guide TDM, were translated to plasma concentration ranges of 0.06–0.26 ng/mL and 0.10–0.93 ng/mL for kidney and lung transplant recipients, respectively.

15 January 2025 in Anesthesiology
Verified
Journal Article
Open access
RVRemco Vellinga
Remco Vellinga
JKJeroen V. Koomen
Jeroen V. Koomen
DEDouglas J. Eleveld
Douglas J. Eleveld
TSThomas Stöhr
Thomas Stöhr
MPMarija Pesic
Marija Pesic
PCPieter J. Colin
Pieter J. Colin
Background: Synergistic effects between opioids and remimazolam on Bispectral Index (BIS) and Modified Observer’s Assessment of Alertness and Sedation (MOAAS) score were previously described. This study aimed to characterize the influence of remifentanil on the sedative properties of remimazolam as measured by MOAAS, BIS, and tolerance to laryngoscopy or tetanic stimulation (TOL or TOTS) and to determine target concentrations that maximize MOAAS 2 or 3. Methods: A three-period, crossover, dose-ranging clinical trial was performed in 24 healthy volunteers. In all periods, remimazolam was administered using a step-up and step-down target controlled infusion protocol (50 to 2,000 ng/ml). Stable remifentanil target concentrations of 0.5 ng/ml and 0.1 to 4.0 ng/ml were maintained in periods 2 and 3, respectively. Remifentanil, remimazolam, and CNS7054 (metabolite) concentrations and MOAAS, BIS, TOL, and TOTS were collected in each step of the target controlled infusion protocol. Data were analyzed using nonlinear mixed-effects models, where P ≤ 0.01 was considered significant. Results: Remifentanil reduced the apparent clearance of CNS7054 with a half-maximum inhibition at 8.0 ng/ml (95% CI, 5.5 to 13.4 ng/ml). A pharmacodynamic interaction was detected on all endpoints. Simulations indicate that the probability of observing a MOAAS 2 or 3 is highest at remimazolam target concentration of 275, 250, or 200 ng/ml combined with 0, 0.1, or 0.5 ng/ml remifentanil resulting in probabilities of 45%, 45%, and 44%, respectively. Additionally, simulations indicate that the highest probability of observing TOTS and TOL was 93.3% and 85.5%, respectively, at the highest studied target concentrations. Conclusions: A pharmacokinetic and pharmacodynamic drug–drug interaction between remimazolam and remifentanil was quantified in this clinical trial. Appropriate target concentrations for MOAAS and BIS could be estimated, but for TOL and TOTS, the trial design did not allow to fully characterize the exposure–response relationship.

12 May 2025 in Anesthesiology
Verified
Journal Article
Open access
PCPieter J. Colin
Pieter J. Colin
LBLynn H. Bichajian
Lynn H. Bichajian
VCValentin R Curt
Valentin R Curt
JKJeroen V. Koomen
Jeroen V. Koomen
TSThomas Stöhr
Thomas Stöhr
KMKeira Mason
Keira Mason
Background: Remimazolam is not approved for use in pediatric patients. The pharmacokinetics of remimazolam have been reported to be similar to those of adult patients after scaling for body size. This article reports on the pharmacokinetics and pharmacodynamics of pediatric patients aged 6 to 18 yr and a subsequent model-based optimization of the used dosing regimen. Methods: Thirty-one patients were included in the trial and stratified across four treatment arms: bolus administration, infusion, bolus plus fentanyl, or infusion plus fentanyl. The University of Michigan (Ann Arbor, Michigan) Sedation Scale (UMSS) was used to assess the depth of sedation. Blood samples were drawn to measure the concentrations of remimazolam and its metabolite CNS7054. Population pharmacokinetic pharmacodynamic modeling was performed in NONMEM (GloboMax LLC, USA). Results: A population pharmacokinetic model was developed for remimazolam and CNS7054. The elimination clearance of remimazolam was 0.70 l · min –1 · 70 kg –1 . A proportional odds model combined with a simplified Minto model described the observed UMSS well. The EC50 of remimazolam for a UMSS score of 3 or greater was 777 ng · ml –1 in the absence of fentanyl, and decreased to 655, 533, and 287 ng/ml for concomitant fentanyl steady state concentrations of 1, 2, or 4 ng · ml –1 , respectively. Simulations confirmed that the studied dosing regimen resulted in 9.2 to 22.0% of patients not reaching a UMSS score of 3 or greater at the end of the induction. Model-based optimization resulted in higher per-kilogram dosages and the removal of the maximum allowable dose. Simulations indicated that the percentage of patients achieving a UMSS score of 3 or greater can be expected to be high (88 to 97%). Conclusions: This study has shown that the pharmacokinetics of remimazolam are likely different between children 6 yr or older and adults (after correcting for size). In addition, the exposure–response relationship shows that to effectively use remimazolam for procedural sedation in children 6 yr or older, the dosing regimen should be modified to allow for higher remimazolam exposures.